Literature DB >> 2119892

Distinct effects of interferon-gamma and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killer-mediated lysis.

R T Maziarz1, S J Mentzer, S J Burakoff, D V Faller.   

Abstract

Various investigators have examined the relationship between tumor cell susceptibility to natural killer (NK) cell lysis and the expression of HLA class I antigens on the tumor cell. There is controversy as to whether or not an inverse relationship exists, and if so, the basis of the relationship between these two phenomena remains undefined. To address these questions, the genomic clones for two HLA antigens were transfected into the erythroleukemia cell line K562, a cell line that is used as the standard to assess human NK and major histocompatibility complex (MHC) nonrestricted cytolysis. Susceptibility to NK lysis was not affected by the de novo expression of HLA antigens on the K562 after DNA mediated gene transfer. Interferon-gamma (IFN-gamma) treatment of K562 induced levels of MHC class I antigen surface expression comparable to those found on the transfected cells; however, the IFN-gamma-treated cells were resistant to NK lysis. When very high levels of surface HLA antigens were induced on the transfectants, a potential effect of class I MHC expression on K562 lysis could be discerned that was distinct from the resistance to NK lysis induced by IFN-gamma-treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119892     DOI: 10.1016/0008-8749(90)90276-w

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1.

Authors:  Ruipeng Wang; Jessica J Jaw; Nicole C Stutzman; Zhongcheng Zou; Peter D Sun
Journal:  J Leukoc Biol       Date:  2011-11-01       Impact factor: 4.962

2.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

3.  Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells.

Authors:  Karen S Anderson; Wanyong Zeng; Tetsuro Sasada; Jaewon Choi; Angelika B Riemer; Mei Su; Donna Drakoulakos; Yoon-Joong Kang; Vladimir Brusic; Catherine Wu; Ellis L Reinherz
Journal:  Cancer Immunol Immunother       Date:  2011-03-13       Impact factor: 6.968

4.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

5.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing.

Authors:  A M Nouri; R F Hussain; A V Dos Santos; M Mansouri; R T Oliver
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.